Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson’s TREMFYA met the primary and major secondary endpoints in a Phase 4 trial of adults with psoriatic arthritis and axial involvement, showing improvements …
TREMFYA Meets Key Goals in Psoriatic Arthritis Study Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) secured U.S. Food and Drug Administration approval for IMAAVY to treat warm autoimmune hemolytic anemia in patients 12 and older who …
FDA Clears J&J’s IMAAVY as First Drug for Rare Blood Disease Read More
WASHINGTON, D.C. — The Federal Trade Commission has urged a federal appeals court to preserve an antitrust lawsuit accusing Johnson & Johnson of unlawfully maintaining its monopoly over the blockbuster …
FTC Backs Antitrust Suit Challenging J&J’s Stelara Monopoly Read More HORSHAM, PA — The U.S. Food and Drug Administration has approved a label expansion for Johnson & Johnson’s (NYSE: JNJ) TREMFYA, allowing the company to market clinical evidence showing the …
FDA Expands TREMFYA Label to Include Joint Damage Data in Psoriatic Arthritis Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has granted Priority Review to its supplemental Biologics License Application for IMAAVY (nipocalimab-aahu) to …
FDA Grants Priority Review to J&J sBLA for IMAAVY in wAIHA Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) recently reported new Phase 3 data showing sustained symptom improvement and reduced antibody levels in patients with generalized myasthenia gravis treated with …
Johnson & Johnson Reports Long-Term Data on Myasthenia Drug Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced recently that its oral psoriasis treatment ICOTYDE (icotrokinra) achieved sustained skin clearance rates through 52 weeks in Phase 3 clinical …
Johnson & Johnson Reports Psoriasis Drug Results From Phase 3 Studies Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and …
FDA Approves Johnson & Johnson Psoriasis Drug ICOTYDE Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults …
FDA Approves TECVAYLI and DARZALEX FASPRO Combo for Multiple Myeloma Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of IMAAVY (nipocalimab-aahu) …
Johnson & Johnson Submits FDA Application for IMAAVY in wAIHA Read More